Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
VANCOUVER, British Columbia, April 02, 2026--$79 million investment from Government of Canada supports $280 million project ...
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the ...
The development of humans and other animals unfolds gradually over time, with cells taking on specific roles and functions via a process called cell fate determination. The fate of individual cells, ...
The key for optimizing cell-line development for antibody derivatives might just be to prioritize early assessment of product ...
Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
A team of researchers at Baylor College of Medicine, St. Jude Children's Research Hospital, Texas Children's Hospital and ...
Advent Technologies Holdings, Inc. ('Advent” or the 'Company”), an innovation driven leader in the fuel cell and hydrogen technology space, has entered into a license and joint development agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results